Sorry, no content matched your criteria.
Featured Story
The BioScience Profit Outlook for the Rest of 2014
With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.
That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.
That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.
Today I want to share with you some of my thinking, expectations, and predictions, as well as my strategy to get us tapped in to a segment of the bioscience market we haven't even touched yet.
This segment has been tremendously profitable for some of the world's biggest drug companies, and I think there are going to be some killer profits for us there, too... Full Story
With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.
That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.
That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.
Today I want to share with you some of my thinking, expectations, and predictions, as well as my strategy to get us tapped in to a segment of the bioscience market we haven't even touched yet.
This segment has been tremendously profitable for some of the world's biggest drug companies, and I think there are going to be some killer profits for us there, too... Full Story